Cancer detection rates and inter-examiner variability of MRI/TRUS fusion targeted biopsy and systematic transrectal biopsy.

CONCLUSION: MRI/TRUS TG in combination with SB had significantly higher detection rates than SB in the RB group only. Differences in detection rates between examiners were dependent on the level of previous experience with TRUS guided biopsy. PMID: 31602045 [PubMed - as supplied by publisher]
Source: Biomedical Papers of the Medical Faculty of the Univ Palacky Olomouc Czech Repub - Category: Biomedical Science Tags: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Source Type: research

Related Links:

Authors: Montgomery B PMID: 31730580 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
Publication date: Available online 15 November 2019Source: Meta GeneAuthor(s): Berjas Abumsimir, Mohammed Mrabti, Abdelilah Laraqui, Ahmed Ameur, Saad Ibnsouda Koraishi, Mohammed Mzibrie, Mohammed Nabil Benchekroun, Hlima Bessi, Ikram Tiabi, Ihsan Almahasneh, Moulay Mustapha EnnajiAbstractThe home box transcription factor gene (HOXB13) plays a certain role in human development and prostate tumorgenesis. Genetic alterations of HOXB13 help to explore the suspected role in prostate cancer. To determine the prevalence and clinical correlates of high-frequent mutational events in home box transcription factor (HOXB13); DNA samp...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
Immunotherapy drugs have so far produced underwhelming results in prostate cancer. Now a team of researchers may have figured out why and how to make these drugs work for prostate cancer patients.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
LEN GOODMAN, best known for being a head judge on TV dance competition Strictly Come Dancing, underwent a secret health battle while on the show that not even the BBC knew about at the time. The star was diagnosed with prostate cancer.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conclusion There is no research on the intraobserver agreement analysis of 68Ga–prostate-specific membrane antigen positron emission tomography/computed tomography in the literature. Our findings are the first ones. The intraobserver agreement was almost perfect. Moreover, although 68Ga–prostate-specific membrane antigen I&T positron emission tomography/computed tomography had moderate interobserver evaluation compliance of the primary tumour, it had excellent interobserver agreement levels in local lymph node metastasis and distant metastasis evaluation.4012501255
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Objective Patients with prostate cancer are monitored by prostate-specific antigen (PSA) evaluation and PET [PET/computed tomography (CT)]. The aim of our study was to evaluate correlations between PSA levels and standardized uptake values (SUV) in patients with recurrent prostate cancer. Methods We analyzed 282 prostate cancer patients undergoing PET-CT due to suspicion of recurrence. Levels of PSA and PSA change per month were analyzed, together with maximum standardized uptake value (SUVmax). Results PET/CT results were positive in 175 patients (62.1%) and negative in 107 patients (37.9%). In the positive group,...
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Conclusion Primary prostatic tumor seems less likely to respond to ADT than nodal or metastatic lesions. Residual primary uptake may guide patient selection for local therapy in (oligo) metastatic prostate cancer.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): L.H. Klotz, N. Axén, S. Grudén, C. Gauffin, J. Giddens, P. Incze, K. Jansz, M. Jievaltas, R. Rendon, A. Ulys, A. Bjartell, T. Tammela
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): L. Moris, T. Van Den Broeck, T. Gevaert, E. Smeets, C. Helsen, F. Handle, H. Van Poppel, W. Everaerts, D. Lambrechts, C. Buerki, E. Davicioni, D. Daelemans, S. Joniau, F. Claessens
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): G.S. Bora, V.K. Sharma, R.S. Mavuduru, S.K. Devana, N. Kakkar, A. Rastogi, A.P. Sharma
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
More News: Biomedical Science | Cancer | Cancer & Oncology | Czechia Health | Prostate Cancer | Study